Phase 2/3 Neutropenia Prevention with Docetaxel
Phase 2/3 Trial for Solid Tumors in which Docetaxel is Approved
The Phase 2/3 trial of Plinabulin with Docetaxel in patients treated with Docetaxel in all solid tumor indications will evaluate the combination for the prevention of Febrile Neutropenia induced by Docetaxel. The Phase 2 study demonstrated solid efficacy in reducing Neutropenia in patients previously treated with docetaxel and displayed a strong safety profile. These results provided a strong basis to initiate the Phase 2/3 study.
The multi-center, randomized, open label trial plans to enroll approximately 100 patients in each arm for a three-month long study.
Study Design and Status
More information on this pivotal trial is available on ClinicalTrial.gov.